# Mark E. Cooper

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-e-cooper/

## Facts

| Field | Value |
| --- | --- |
| Citations | 73,774 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 124 |
| i10-index | 438 |
| Last Known Institution | Monash University |
| OpenAlex ID | https://openalex.org/A5062670268 |
| ORCID iD | https://orcid.org/0000-0001-7785-2488 |
| Works | 707 |

## Researcher papers

Showing 12 of 14.

- [Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy](https://scholariq.org/papers/effects-of-losartan-on-renal-and-cardiovascular-outcomes-in-patients-with-type-2/)
- [Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/intensive-blood-glucose-control-and-vascular-outcomes-in-patients-with-type-2/)
- [A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/a-trial-of-darbepoetin-alfa-in-type-2-diabetes-and-chronic-kidney-disease/)
- [Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future](https://scholariq.org/papers/pathophysiology-and-treatment-of-type-2-diabetes-perspectives-on-the-past/)
- [Diabetic kidney disease](https://scholariq.org/papers/diabetic-kidney-disease/)
- [Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk](https://scholariq.org/papers/effect-of-linagliptin-vs-placebo-on-major-cardiovascular-events-in-adults-with/)
- [Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes](https://scholariq.org/papers/albuminuria-and-kidney-function-independently-predict-cardiovascular-and-renal/)
- [Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL](https://scholariq.org/papers/proteinuria-a-target-for-renoprotection-in-patients-with-type-2-diabetic/)
- [Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy](https://scholariq.org/papers/albuminuria-a-therapeutic-target-for-cardiovascular-protection-in-type-2/)
- [Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy](https://scholariq.org/papers/effect-of-finerenone-on-albuminuria-in-patients-with-diabetic-nephropathy/)
- [Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes](https://scholariq.org/papers/follow-up-of-blood-pressure-lowering-and-glucose-control-in-type-2-diabetes/)
- [Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes](https://scholariq.org/papers/impact-of-age-age-at-diagnosis-and-duration-of-diabetes-on-the-risk-of/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Advanced Glycation End Products research](https://scholariq.org/topics/advanced-glycation-end-products-research/)
- [Blood Pressure and Hypertension Studies](https://scholariq.org/topics/blood-pressure-and-hypertension-studies/)
- [Renin-Angiotensin System Studies](https://scholariq.org/topics/renin-angiotensin-system-studies/)

## Researcher university

- [Monash University](https://scholariq.org/institutions/monash-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.